These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31387920)

  • 21. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the immune system in cancer.
    Chaudhuri D; Suriano R; Mittelman A; Tiwari RK
    Curr Pharm Biotechnol; 2009 Feb; 10(2):166-84. PubMed ID: 19199949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immune system--is it relevant to cancer development, progression and treatment?
    Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma.
    Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ
    Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.
    Abu Eid R; Razavi GS; Mkrtichyan M; Janik J; Khleif SN
    Cancer Immunol Res; 2016 May; 4(5):377-82. PubMed ID: 27196429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoimmunotherapy.
    Emens LA
    Cancer J; 2010; 16(4):295-303. PubMed ID: 20693839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.
    Wanderley CW; Colón DF; Luiz JPM; Oliveira FF; Viacava PR; Leite CA; Pereira JA; Silva CM; Silva CR; Silva RL; Speck-Hernandez CA; Mota JM; Alves-Filho JC; Lima-Junior RC; Cunha TM; Cunha FQ
    Cancer Res; 2018 Oct; 78(20):5891-5900. PubMed ID: 30104241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment duration with immune-based therapies in Cancer: an enigma.
    Bantia S; Choradia N
    J Immunother Cancer; 2018 Dec; 6(1):143. PubMed ID: 30518409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
    Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
    Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
    [No Abstract]   [Full Text] [Related]  

  • 35. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV.
    Pakravan N; Hassan ZM
    Immunotherapy; 2018 Mar; 10(3):213-219. PubMed ID: 29370722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer immunotherapy, mathematical modeling and optimal control.
    Castiglione F; Piccoli B
    J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
    Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
    Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.